Goldman Sachs’s Quince Therapeutics QNCX Stock Holding History

Goldman Sachs’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-25	Closed	-$458K	–	6657
2021 Q3	$458K	Hold	25	–	–	﹤0.01%	5249
2021 Q2	$265K	Buy	+25	New	+$210K	﹤0.01%	5594

Other funds holding QNCX

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs's QNCX Position: Q2 2026 in Review

Goldman Sachs sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 80 shares — an estimated $1.63K sold.

Goldman Sachs first reported a position in QNCX in Q2 2019 and held it in 15 quarters. The position peaked at $3.74M in Q3 2021. 26 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

Goldman Sachs reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
Goldman Sachs sold 80 Quince Therapeutics shares in Q2 2026, an estimated $1.63K.
Goldman Sachs first reported a position in Quince Therapeutics in Q2 2019 and held it in 15 quarters.
Goldman Sachs's Quince Therapeutics position peaked at $3.74M in Q3 2021.
26 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.